Navigation Links
Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
Date:4/3/2009

linical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; the Phase 3 clinical studies were completed in October 2007; the BLA was filed with the FDA in October 2008 and the FDA granted priority review status in December 2008. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: http://www.savient.com.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. In particular, any statements about the expected closing of the offering are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the satisfaction of the closing conditions for the offering and other important factors set forth more fully under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2008 and elsewhere in our reports filed with the Securities and Exchange Commission to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-loo
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
2. Savient Announces Appointment of David Gionco as Chief Financial Officer
3. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Submits Biologics License Application (BLA) for pegloticase
6. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
7. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
8. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
9. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
10. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
11. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Bill Jacobs Automotive, a group of car dealerships headquartered in ... Heartland Blood Center and offering free oil change coupons for ... Saturday, Jan. 18 at the Bill Jacobs Cadillac and Chevrolet ... http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs Auto ...
(Date:1/15/2014)... 2014 Cynvenio, a cancer diagnostics company ... genomic analysis of tumor cells in the bloodstream, today ... cancer decision support application powered by CollabRx, Inc. ... genomic test, Therapy Finder will provide breast cancer patients ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2
... 1 /PRNewswire-FirstCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RVX) is pleased ... on May 8, 2008 at 9:00 pm MDT ... and the business aspects of the Company. Following ... answer session., The webcast can be accessed ...
... - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... today announced that it has received 510(k),clearance from ... begin,marketing sizes 3-0 and 4-0 of its Quill ... SRS PDO is a longer-lasting,absorbable suture, which is ...
... SOUTH SAN FRANCISCO, Calif., May 1 Renovis,Inc. (Nasdaq: ... the,adoption of the merger agreement with Evotec AG (Frankfurt ... today. The merger is,expected to close by May 5, ... share of Renovis common,stock will be automatically converted into ...
Cached Biology Technology:Resverlogix Notice of Conference Call & Webcast 2Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 2Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 3Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 4Renovis Stockholders Approve Acquisition by Evotec 2
(Date:4/23/2014)... greater prevalence of asthma, allergies and other chronic inflammatory ... due in part to their reduced exposure to the ... new scientific paper. , The article, published in the ... people living in urban centers who have less access ... chronic inflammation, a condition caused by immune system dysfunction. ...
(Date:4/23/2014)... with Huntington,s disease, most in their mid-thirties and ... and behavioral decline within two decades. "Mutant" protein ... genetic disease, have been the primary focus of ... to new research from Prof. Gerardo Lederkremer and ... of Cell Research and Immunology, in collaboration with ...
(Date:4/23/2014)... 23, 2014) People who have had a stroke, ... neurological function. However, a study conducted in Taiwan, that ... Cell Transplantation , but is currently freely available on-line ... has found that when one group of stroke victims ... directly into the brain and a similar group did ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3Autologous stem cell therapy improves motor function in chronic stroke victims 2
... University of Leicester and part-funded by The Leverhulme Trust aims ... By bringing together an artist and a neuroscientist, both ... perception. In the process of the research, both artist and ... the eye of the beholder. Rodrigo Quian Quiroga, Neuroscientist ...
... opinion that inflammation in adipose tissue may cause insulin resistance, ... Swedish medical university Karolinska Institutet, published in the New ... in the body fat is only pernicious. Instead the findings ... necessary for fat cell turnover in the lean, healthy state. ...
... not just thinking big but also very, very, very ... director of Binghamton University,s Center for Advanced Sensors and ... that would detect and identify engineered nanoparticles. Her research ... the environmental release and transformation of these particles. ...
Cached Biology News:Beauty is in the eye of the beholder? 2Inflammation in body fat is not only pernicious 2Chemist monitors nanotechnology's environmental impact 2
A univariate (peak height or area) quantitative multi-component analysis package....
... The micro 1 is a dramatic breakthrough ... from 1mL with 10nL resolution, the micro 1 ... benchtop dispenser. And, the micro 1 never needs ... , Touch Screen programming on an LCD Display ...
... microscopes offer all of the features of ... Equipped with Koehler illumination, a centerable condenser ... B3 is the workhorse of Motic's range ... the need for re-focusing following a change ...
... Dye Primer Manual Cycle Sequencing Kit is ... primers and high-resolution fluorescence scanners. Sequencing reactions ... slab gel electrophoresis and scanning of the ... The kit components have been optimized ...
Biology Products: